Prostate Cancer
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
January 27, 2023
Acceptability of a virtual prostate cancer survivorship care model in regional Australia: A qualitative exploratory study.
January 27, 2023
Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
January 27, 2023
Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.
January 27, 2023
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
January 26, 2023
Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials.
January 26, 2023
Outcomes of Robot-assisted Radical Prostatectomy with the Hugo RAS Surgical System: Initial Experience at a High-volume Robotic Center.
January 25, 2023
Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysis.
January 25, 2023
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
January 25, 2023